Provectus Biopharmaceuticals Inc (OP:PVCT)

0.0544 -0.0027 (-4.73%)

Delayed Quote Updated: 12:43 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	425,782
Open	0.0540
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	0.0571
Today's Range	0.0500 - 0.0544
52wk Range	0.0380 - 0.0900
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Noninvasive Eye Infection Treatment Shows Promise

January 09, 2025

(NewsUSA) - Those who suffer from eye infections that threaten a person’s vision have a new treatment option that is noninvasive and counters the problem of antibiotic resistance, based on recent...

Via NewsUSA

PVCT Stock Earnings: Provectus Reported Results for Q2 2024 ↗

August 13, 2024

Provectus just reported results for the second quarter of 2024.

Via InvestorPlace

Performance

YTD	-14.7%	-14.7%
1 Month	-3.7%	-3.7%
3 Month	-21.8%	-21.8%
6 Month	+12.6%	+12.6%
1 Year	-38.9%	-38.9%

More News

PVCT Stock Earnings: Provectus Reported Results for Q1 2024 ↗

May 14, 2024

Via InvestorPlace

PVCT Stock Earnings: Provectus Reported Results for Q4 2023 ↗

March 28, 2024

Via InvestorPlace

Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗

January 17, 2023

Via Benzinga

Provectus Biopharmaceuticals Announces Decision to Not Undertake Reverse Split of Outstanding and Authorized Equities in 2022; Expects to Seek Same Stockholder Approval Again in 2023

December 12, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Announces New Data from Combination Therapy Trial of Small Molecule Cancer Immunotherapy PV-10® and Keytruda® for First-Line Stage III Melanoma at Melanoma Bridge 2022

December 01, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Announces Acceptance of Small Molecule Cancer Immunotherapy PV-10® Stage III Melanoma Abstract at Melanoma Bridge 2022

November 10, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Announces World Health Organization Selection of “Rose Bengal Sodium” as International Nonproprietary Name for Active Pharmaceutical Ingredient

November 02, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Expands Research Collaboration with The Rockefeller University to Investigate Clinical-Stage Immuno-Dermatology Agent PH-10 for Skin Inflammation

October 25, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Texas Medical Branch at Galveston to Investigate Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal for Wound Healing

September 29, 2022

From Provectus Biopharmaceuticals Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Provectus Biopharmaceuticals Inc publicly traded?

Yes, Provectus Biopharmaceuticals Inc is publicly traded.

What exchange does Provectus Biopharmaceuticals Inc trade on?

Provectus Biopharmaceuticals Inc trades on the OTC Traded

What is the ticker symbol for Provectus Biopharmaceuticals Inc?

The ticker symbol for Provectus Biopharmaceuticals Inc is PVCT on the OTC Traded

What is the current price of Provectus Biopharmaceuticals Inc?

The current price of Provectus Biopharmaceuticals Inc is 0.0544

When was Provectus Biopharmaceuticals Inc last traded?

The last trade of Provectus Biopharmaceuticals Inc was at 10/01/26 12:43 PM ET